Isatuximab

Trade Name: 
Sarclisa
Manufacturer/Distributor: 
sanofi-aventis Canada Inc.
Classification: 
Antineoplastic agent, monoclonal antibody
ATC Class: 
L01XC38 - isatuximab
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2020/04/29
Date Marketed in Canada (yyyy/mm/dd): 
2020/07/03
Presentation: 
Solution for infusion: 20 mg/mL. DIN: 02498243
Comments: 
Used in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies ncluding lenalidomide and a proteasome inhibitor.